Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADXN Addex Therapeutics	$7.92 -7.8%	$8.62	$6.51 ▼ $13.27	$8.39M	1.65	94,651 shs	2,302 shs
APRE Aprea Therapeutics	$1.69 +0.9%	$1.74	$1.41 ▼ $5.01	$9.32M	1.19	27,795 shs	69,714 shs
CPMD Golden Dragon	$0.00 -2.6%	$0.00	$0.00 ▼ $0.01	$2.51M	2.43	194,394 shs	600,937 shs
GLYC GlycoMimetics	$0.16 -6.6%	$13.48	$14.06 ▼ $63.00	$10.00M	1.62	66,645 shs	1.05 million shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADXN Addex Therapeutics	-4.52%	-5.69%	-0.81%	+10.88%	+2.37%
APRE Aprea Therapeutics	+0.60%	-5.65%	-4.84%	+11.30%	-58.15%
CPMD Golden Dragon	0.00%	0.00%	+21.88%	-11.36%	-62.86%
GLYC GlycoMimetics	0.00%	0.00%	0.00%	-99.30%	-99.49%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADXN Addex Therapeutics	2.4057 of 5 stars	3.5	3.0	0.0	0.0	2.2	0.8	0.6
APRE Aprea Therapeutics	2.9365 of 5 stars	3.5	3.0	0.0	0.0	2.7	0.8	1.3
CPMD Golden Dragon	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
GLYC GlycoMimetics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADXN Addex Therapeutics	3.00	Buy	$30.00	278.84% Upside
APRE Aprea Therapeutics	3.00	Buy	$15.50	819.88% Upside
CPMD Golden Dragon	0.00	N/A	N/A	N/A
GLYC GlycoMimetics	2.50	Moderate Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest CPMD, GLYC, ADXN, and APRE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
6/26/2025	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADXN Addex Therapeutics	$460K	18.25	N/A	N/A	$10.37 per share	0.76
APRE Aprea Therapeutics	$1.50M	6.21	N/A	N/A	$3.55 per share	0.47
CPMD Golden Dragon	$820K	3.06	N/A	N/A	($0.03) per share	-0.13
GLYC GlycoMimetics	$10K	1,000.25	N/A	N/A	$0.08 per share	1.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADXN Addex Therapeutics	$8.02M	-$0.34	N/A	∞	N/A	3,584.49%	-54.27%	-49.15%	9/1/2025 (Estimated)
APRE Aprea Therapeutics	-$12.96M	-$2.37	N/A	N/A	N/A	-1,095.02%	-68.39%	-55.74%	8/11/2025 (Estimated)
CPMD Golden Dragon	-$9.91M	-$0.02	N/A	∞	N/A	N/A	N/A	-56.69%	N/A
GLYC GlycoMimetics	-$37.88M	-$0.46	N/A	N/A	N/A	N/A	-230.74%	-177.39%	8/6/2025 (Estimated)

Latest CPMD, GLYC, ADXN, and APRE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	APRE Aprea Therapeutics	-$0.77	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	APRE Aprea Therapeutics	-$0.6543	-$0.66	-$0.0057	-$0.66	N/A	$0.16 million
5/14/2025	Q1 2025	GLYC GlycoMimetics	-$5.00	-$4.00	+$1.00	-$0.04	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADXN Addex Therapeutics	N/A	N/A	N/A	N/A	N/A
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
CPMD Golden Dragon	N/A	N/A	N/A	N/A	N/A
GLYC GlycoMimetics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADXN Addex Therapeutics	N/A	3.02	3.02
APRE Aprea Therapeutics	N/A	5.90	5.90
CPMD Golden Dragon	N/A	0.05	0.01
GLYC GlycoMimetics	N/A	1.92	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADXN Addex Therapeutics	16.14%
APRE Aprea Therapeutics	34.19%
CPMD Golden Dragon	N/A
GLYC GlycoMimetics	75.19%

Insider Ownership

Company	Insider Ownership
ADXN Addex Therapeutics	15.00%
APRE Aprea Therapeutics	13.63%
CPMD Golden Dragon	1.27%
GLYC GlycoMimetics	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADXN Addex Therapeutics	30	1.06 million	901,000	Not Optionable
APRE Aprea Therapeutics	7	5.53 million	4.78 million	No Data
CPMD Golden Dragon	4	660.63 million	652.24 million	Not Optionable
GLYC GlycoMimetics	50	64.53 million	58.90 million	Optionable

CPMD, GLYC, ADXN, and APRE Headlines

Recent News About These Companies

Crescent Biopharma Inc.

June 24, 2025 | barrons.com

LifeSci Capital Initiates Coverage of GlycoMimetics (CBIO) with Outperform Recommendation

June 20, 2025 | msn.com

GlycoMimetics trading halted, news pending

June 14, 2025 | msn.com

GlycoMimetics announces 1-for-100 reverse stock split

June 7, 2025 | investing.com

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

June 5, 2025 | businesswire.com

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

May 16, 2025 | businesswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – GLYC,

May 6, 2025 | bakersfield.comB

Crescent Biopharma Appoints David Lubner to Board of Directors

April 28, 2025 | globenewswire.com

GlycoMimetics Stock Short Interest Report | NASDAQ:GLYC | Benzinga

April 18, 2025 | benzinga.com

Crescent moon shot to scale the Summit in VEGFxPD-1

April 5, 2025 | bioworld.comB

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

April 3, 2025 | globenewswire.com

Cantor Fitzgerald Initiates Coverage of GlycoMimetics (GLYC) with Overweight Recommendation

March 22, 2025 | msn.com

Cantor Fitzgerald Initiates Coverage of GlycoMimetics (GLYC) with Overweight Recommendation

March 22, 2025 | msn.com

Crescent Biopharma initiated with an Overweight at Cantor Fitzgerald

March 22, 2025 | markets.businessinsider.com

Acute Myeloid Leukemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

March 7, 2025 | theglobeandmail.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

March 5, 2025 | prnewswire.com

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

February 26, 2025 | globenewswire.com

US Penny Stocks To Watch In February 2025

February 20, 2025 | finance.yahoo.com

Top 5 Biotech Stocks That Got Most Retail Buzz Last Week

February 17, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

CPMD, GLYC, ADXN, and APRE Company Descriptions

Addex Therapeutics NASDAQ:ADXN

$7.92 -0.67 (-7.81%)

As of 12:15 PM Eastern

Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.

Aprea Therapeutics NASDAQ:APRE

$1.68 +0.02 (+0.90%)

As of 12:21 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Golden Dragon OTCMKTS:CPMD

$0.0038 0.00 (-2.56%)

As of 11:12 AM Eastern

CannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.

GlycoMimetics NASDAQ:GLYC

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time